FDC Limited — Updates, 28-05-2026: Press Release (Revised)
28-05-2026 | 10:55 am
28-05-2026 | 10:55 am
FDC posted robust Q4 FY26 results: Revenue surged 18.9% to 585 Cr, and PAT jumped 167.4% to 103 Cr, boosted by strong Export Formulations and API growth, including a US business turnaround. The company also received U.S. FDA approval for Fluconazole Tablets.
No comments yet. Be the first to comment!
